Targeting intracellular signaling: a novel approach to vaccination

References

• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol.7, 145–173 (1989).
   PubMed Web of Science ®Google Scholar
• Burdin N, Guy B, Moingeon P. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs18(2), 79–93 (2004).
   PubMed Web of Science ®Google Scholar
• Kornbluth RS, Stone GW. Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J. Leukoc. Biol.80(5), 1084–1102 (2006).
   PubMedGoogle Scholar
• Wales JR, Baird MA, Davies NM, Buchan GS. Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigenicity but not their protective efficacy. Vaccine23(17–18), 2339–2341 (2005).
   PubMedGoogle Scholar
• Young SL, Wilson M, Wilson S et al. Transcutaneous vaccination with virus-like particles. Vaccine24(26), 5406–5412 (2006).
   PubMedGoogle Scholar
• Williman J, Lockhart E, Slobbe L, Buchan G, Baird M. The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun. Vaccine24(21), 4471–4474 (2006).
   PubMedGoogle Scholar
• Kovacs JA, Lempicki RA, Sidorov IA et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J. Clin. Invest.115(8), 2139–2148 (2005).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma – predictors of response. Semin. Oncol.33(5), 583–587 (2006).
   PubMed Web of Science ®Google Scholar
• McDermott DF. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin. Cancer Res.13(2 Pt 2), 716s–720s (2007).
   PubMed Web of Science ®Google Scholar
• Lemckert AA, Goudsmit J, Barouch DH. Challenges in the search for an HIV vaccine. Eur. J. Epidemiol.19(6), 513–516 (2004).
   PubMedGoogle Scholar
• Tritel M, Stoddard AM, Flynn BJ et al. Prime–boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J. Immunol.171(5), 2538–2547 (2003).
   PubMed Web of Science ®Google Scholar
• Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res.7(3), 167–202 (2001).
   PubMedGoogle Scholar
• Lodes MJ, Cong Y, Elson CO et al. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest.113(9), 1296–1306 (2004).
   PubMed Web of Science ®Google Scholar
• Sacre SM, Andreakos E, Kiriakidis S et al. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am. J. Pathol.170(2), 518–525 (2007).
   PubMed Web of Science ®Google Scholar
• Deng GM, Nilsson IM, Verdrengh M, Collins LV, Tarkowski A. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat. Med.5(6), 702–705 (1999).
   PubMed Web of Science ®Google Scholar
• Visser L, Melief MJ, van Riel D et al. Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates. Am. J. Pathol.169(5), 1671–1685 (2006).
   PubMedGoogle Scholar
• Nguyen MD, D’Aigle T, Gowing G, Julien JP, Rivest S. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J. Neurosci.24(6), 1340–1349 (2004).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol.174(12), 7676–7683 (2005).
   PubMed Web of Science ®Google Scholar
• Nohria A, Rubin RH. Cytokines as potential vaccine adjuvants. Biotherapy7(3–4), 261–269 (1994).
   PubMedGoogle Scholar
• Wales J, Baird M, Davies N, Buchan G. Fusion of interleukin-2 to subunit antigens increase their antigenicity in vitro due to an interleukin-2 receptor β-mediated antigen uptake mechanism. Scand. J. Immunol.58(3), 367–373 (2003).
   PubMedGoogle Scholar
• Li Q, Verma IM. NF-κB regulation in the immune system. Nat. Rev. Immunol.2(10), 725–734 (2002).
   PubMed Web of Science ®Google Scholar
• Drexler S, Turner J, Foxwell BM. Clinical prospects of NF-κB inhibitors to further targeted therapies in rheumatology. In: Contemporary Targeted Therapies in Rheumatology. Smolen J, Lipsky P (Eds). Informa Healthcare, (2007) (In press).
   Google Scholar
• Vermeulen L, Vanden Berghe W, Haegeman G. Regulation of NF-κB transcriptional activity. Cancer Treat. Res.130, 89–102 (2006).
   PubMedGoogle Scholar
• Lad SP, Li J, da Silva Correia J et al. Cleavage of p65/RelA of the NF-κB pathway by Chlamydia. Proc. Natl Acad. Sci. USA104(8), 2933–2938 (2007).
   PubMed Web of Science ®Google Scholar
• Hiscott J, Nguyen TL, Arguello M, Nakhaei P, Paz S. Manipulation of the nuclear factor-κB pathway and the innate immune response by viruses. Oncogene25(51), 6844–6867 (2006).
   PubMed Web of Science ®Google Scholar
• Li K, Foy E, Ferreon JC et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad. Sci. USA102(8), 2992–2997 (2005).
   PubMed Web of Science ®Google Scholar
• Stack J, Haga IR, Schroder M et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med.201(6), 1007–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Tait SW, Reid EB, Greaves DR, Wileman TE, Powell PP. Mechanism of inactivation of NF-κB by a viral homologue of Iκbα. Signal-induced release of Iκbα results in binding of the viral homologue to NF-κB. J. Biol. Chem.275(44), 34656–34664 (2000).
   PubMed Web of Science ®Google Scholar
• Pikarsky E, Ben-Neriah Y. NF-κB inhibition: a double-edged sword in cancer? Eur. J. Cancer42(6), 779–784 (2006).
   PubMed Web of Science ®Google Scholar
• Wei L, Sandbulte MR, Thomas PG et al. NFκB negatively regulates interferon-induced gene expression and anti-influenza activity. J. Biol. Chem.281(17), 11678–11684 (2006).
   PubMed Web of Science ®Google Scholar
• Yang CH, Murti A, Pfeffer LM. Interferon induces NF-κB-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-κB activation to promote cell survival. J. Biol. Chem.280(36), 31530–31536 (2005).
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Dudziak D, Dirmeier U et al. Active NF-κB signalling is a prerequisite for influenza virus infection. J. Gen. Virol.85(Pt 8), 2347–2356 (2004).
   PubMed Web of Science ®Google Scholar
• Yin L, Wu L, Wesche H et al. Defective lymphotoxin-β receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science291(5511), 2162–2165 (2001).
   PubMed Web of Science ®Google Scholar
• Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature385(6616), 540–544 (1997).
   PubMed Web of Science ®Google Scholar
• Pan Q, Kravchenko V, Katz A et al. NF-κB-inducing kinase regulates selected gene expression in the Nod2 signaling pathway. Infect. Immun.74(4), 2121–2127 (2006).
   PubMed Web of Science ®Google Scholar
• Smith C, Andreakos E, Crawley JB et al. NF-κB-inducing kinase is dispensable for activation of NF-κB in inflammatory settings but essential for lymphotoxin β receptor activation of NF-κB in primary human fibroblasts. J. Immunol.167(10), 5895–5903. (2001).
   PubMed Web of Science ®Google Scholar
• Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol.25(6), 280–288 (2004).
   PubMed Web of Science ®Google Scholar
• Aya K, Alhawagri M, Hagen-Stapleton A et al. NF-κB-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J. Clin. Invest.115(7), 1848–1854 (2005).
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Nakamura Y, Suzuka H et al. A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice. Eur. J. Immunol.24(2), 429–434 (1994).
   PubMedGoogle Scholar
• Tumanov AV, Grivennikov SI, Shakhov AN et al. Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunol. Rev.195, 106–116 (2003).
   PubMedGoogle Scholar
• Lu LF, Gondek DC, Scott ZA, Noelle RJ. NF κ B-inducing kinase deficiency results in the development of a subset of regulatory T cells, which shows a hyperproliferative activity upon glucocorticoid-induced TNF receptor family-related gene stimulation. J. Immunol.175(3), 1651–1657 (2005).
   PubMedGoogle Scholar
• Andreakos E, Williams RO, Wales J, Foxwell BM, Feldmann M. Activation of NF-κB by the intracellular expression of NF-κB-inducing kinase acts as a powerful vaccine adjuvant. Proc. Natl Acad. Sci. USA103(39), 14459–14464 (2006).
   PubMed Web of Science ®Google Scholar
• Takeshita F, Tanaka T, Matsuda T et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J. Virol.80(13), 6218–6224 (2006).
   PubMed Web of Science ®Google Scholar
• Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signaling. Stem Cells19(5), 378–387 (2001).
   PubMed Web of Science ®Google Scholar
• Ryo A, Suizu F, Yoshida Y et al. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell12(6), 1413–1426 (2003).
   PubMed Web of Science ®Google Scholar
• Mansell A, Smith R, Doyle SL et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol.7(2), 148–155 (2006).
   PubMed Web of Science ®Google Scholar
• Nakagawa R, Naka T, Tsutsui H et al. SOCS-1 participates in negative regulation of LPS responses. Immunity17(5), 677–687 (2002).
   PubMed Web of Science ®Google Scholar
• Park SH, Kim KE, Hwang HY, Kim TY. Regulatory effect of SOCS on NF-κB activity in murine monocytes/macrophages. DNA Cell. Biol.22(2), 131–139 (2003).
   PubMedGoogle Scholar
• Baetz A, Frey M, Heeg K, Dalpke AH. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J. Biol. Chem.279(52), 54708–54715 (2004).
   PubMed Web of Science ®Google Scholar
• Shen L, Evel-Kabler K, Strube R, Chen SY. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol.22(12), 1546–1553 (2004).
   PubMed Web of Science ®Google Scholar
• Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY. SOCS1 restricts dendritic cells’ ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J. Clin. Invest.116(1), 90–100 (2006).
   PubMedGoogle Scholar
• Song XT, Evel-Kabler K, Rollins L et al. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med.3(1), e11 (2006).
   PubMed Web of Science ®Google Scholar
• Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-κ B leads to multifocal defects in immune responses. Cell80(2), 321–330 (1995).
   PubMed Web of Science ®Google Scholar
• Girardin SE, Boneca IG, Carneiro LA et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science300(5625), 1584–1587 (2003).
   PubMed Web of Science ®Google Scholar
• Girardin SE, Travassos LH, Herve M et al. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J. Biol. Chem.278(43), 41702–41708 (2003).
   PubMed Web of Science ®Google Scholar
• Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol.14(21), 1929–1934 (2004).
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Natsukawa T et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol.5(7), 730–737 (2004).
   PubMed Web of Science ®Google Scholar
• Puri N, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. J. Control Release69(1), 69–80 (2000).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo M et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol.23(9), 2004–2011 (2005).
   PubMed Web of Science ®Google Scholar
• Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci.30(3), 151–159 (2005).
   PubMed Web of Science ®Google Scholar
• Uehara A, Yang S, Fujimoto Y et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell. Microbiol.7(1), 53–61 (2005).
   PubMed Web of Science ®Google Scholar
• Viala J, Chaput C, Boneca IG et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat. Immunol.5(11), 1166–1174 (2004).
   PubMed Web of Science ®Google Scholar
• Chamaillard M, Hashimoto M, Horie Y et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol.4(7), 702–707 (2003).
   PubMed Web of Science ®Google Scholar
• Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol.6(9), 644–658 (2006).
   PubMed Web of Science ®Google Scholar
• Tough DF. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk. Lymphoma45(2), 257–264 (2004).
   PubMed Web of Science ®Google Scholar
• Buelens C, Bartholome EJ, Amraoui Z et al. Interleukin-3 and interferon β cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood99(3), 993–998 (2002).
   PubMedGoogle Scholar
• Luft T, Luetjens P, Hochrein H et al. IFN-α enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int. Immunol.14(4), 367–380 (2002).
   PubMed Web of Science ®Google Scholar
• Le Bon A, Schiavoni G, D’Agostino G et al. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity14(4), 461–470 (2001).
   PubMed Web of Science ®Google Scholar
• Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today17(8), 369–372 (1996).
   PubMedGoogle Scholar
• Le Bon A, Thompson C, Kamphuis E et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol.176(4), 2074–2078 (2006).
   PubMed Web of Science ®Google Scholar
• Sasaki S, Amara RR, Yeow WS, Pitha PM, Robinson HL. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J. Virol.76(13), 6652–6659 (2002).
   PubMedGoogle Scholar
• Sasaki S, Amara RR, Oran AE, Smith JM, Robinson HL. Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat. Biotechnol.19(6), 543–547 (2001).
   PubMed Web of Science ®Google Scholar
• Kojima Y, Jounai N, Takeshita F et al. The degree of apoptosis as an immunostimulant for a DNA vaccine against HIV-1 infection. Vaccine25(3), 438–445 (2007).
   PubMed Web of Science ®Google Scholar
• Sauter B, Albert ML, Francisco L et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med.191(3), 423–434 (2000).
   PubMed Web of Science ®Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature392(6671), 86–89 (1998).
   PubMed Web of Science ®Google Scholar
• Janssen E, Tabeta K, Barnes MJ et al. Efficient T cell activation via a Toll-interleukin 1 receptor-independent pathway. Immunity24(6), 787–799 (2006).
   PubMed Web of Science ®Google Scholar
• Davenport MP, Ribeiro RM, Zhang L, Wilson DP, Perelson AS. Understanding the mechanisms and limitations of immune control of HIV. Immunol. Rev.216, 164–175 (2007).
   PubMed Web of Science ®Google Scholar
• Spier RE. On the need for, and the delivery of, cross-protective vaccines. Vaccine23(17–18), 2027–2029 (2005).
   PubMedGoogle Scholar